Alnylam Pharmaceuticals (ALNY) Competitors $452.33 -1.85 (-0.41%) Closing price 04:00 PM EasternExtended Trading$451.98 -0.35 (-0.08%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, INCY, UTHR, NBIX, BMRN, and EXELShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Do institutionals & insiders hold more shares of ALNY or AMGN? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, ALNY or AMGN? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B26.37-$278.16M-$2.47-183.13Amgen$33.42B4.60$4.09B$12.2323.35 Do analysts rate ALNY or AMGN? Alnylam Pharmaceuticals currently has a consensus price target of $405.33, suggesting a potential downside of 10.39%. Amgen has a consensus price target of $304.43, suggesting a potential upside of 6.59%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 22 Buy rating(s) 0 Strong Buy rating(s) 2.85Amgen 2 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.33 Is ALNY or AMGN more profitable? Amgen has a net margin of 18.96% compared to Alnylam Pharmaceuticals' net margin of -12.96%. Amgen's return on equity of 174.71% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.96% -273.52% -7.39% Amgen 18.96%174.71%13.12% Which has more volatility and risk, ALNY or AMGN? Alnylam Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Does the media favor ALNY or AMGN? In the previous week, Amgen had 33 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 58 mentions for Amgen and 25 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.30 beat Amgen's score of 1.13 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 16 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 44 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive SummaryAmgen beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.53B$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.01%P/E Ratio-183.137.3622.5622.49Price / Sales26.37398.26463.84113.07Price / CashN/A44.6737.7359.36Price / Book236.828.0910.046.68Net Income-$278.16M-$54.08M$3.27B$265.59M7 Day Performance-3.26%2.25%3.17%3.42%1 Month Performance39.27%3.41%4.34%1.09%1 Year Performance61.14%18.61%44.12%23.84% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.1677 of 5 stars$452.33-0.4%$405.33-10.4%+62.1%$59.53B$2.25B-183.132,230AMGNAmgen4.7443 of 5 stars$292.62-1.3%$303.76+3.8%-11.9%$157.53B$33.42B23.9328,000Positive NewsAnalyst ForecastGILDGilead Sciences4.9733 of 5 stars$117.99-0.3%$114.82-2.7%+47.9%$146.40B$28.75B23.5017,600Positive NewsVRTXVertex Pharmaceuticals4.9407 of 5 stars$389.88-0.7%$497.10+27.5%-19.0%$99.96B$11.02B27.876,100Positive NewsREGNRegeneron Pharmaceuticals4.8516 of 5 stars$573.91-1.1%$829.65+44.6%-51.2%$60.83B$14.20B14.4615,106Trending NewsAnalyst ForecastBIIBBiogen4.839 of 5 stars$135.91-1.9%$185.74+36.7%-32.9%$19.93B$9.68B12.997,605Positive NewsINCYIncyte4.6676 of 5 stars$84.92-2.3%$81.20-4.4%+29.3%$16.58B$4.24B19.302,617Positive NewsUTHRUnited Therapeutics4.9273 of 5 stars$314.10+0.3%$382.00+21.6%-12.6%$14.17B$2.88B12.261,305News CoveragePositive NewsAnalyst RevisionNBIXNeurocrine Biosciences4.891 of 5 stars$133.14+0.2%$160.90+20.9%-9.5%$13.20B$2.36B39.391,800Positive NewsBMRNBioMarin Pharmaceutical4.9963 of 5 stars$57.44-0.2%$93.17+62.2%-35.2%$11.03B$2.85B17.043,040Positive NewsEXELExelixis4.8776 of 5 stars$37.76-1.4%$44.06+16.7%+49.7%$10.16B$2.17B18.151,147Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access